Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: ⟹ activities or the?

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND")...

China approves the Corina Intrauterine Drug-Eluting System as a novel treatment for moderate-to-severe intrauterine adhesions (IUA)

Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who...

Trinity Life Sciences introduces new customer engagement solutions, leveraging its deep commercial insight and renowned technology platform

Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces new Customer Engagement solutions leveraging both Trinity’s deep commercial insight and recognized technology platform. The new...

Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in...

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that its Unidose Liquid System (Unidose) is the delivery system approved with neffy® (epinephrine nasal spray), the first and...

Derm-Biome Pharmaceuticals to develop skincare treatment that promotes skin health and longevity

Derm-Biome Pharmaceuticals Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy aging, is excited to announce the development of a novel, science-backed skincare treatment aimed at targeting some of the root causes...

Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma

Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior...

Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies

Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, today announced the first cohort of participants has been dosed in a Phase 1 trial...

Clarivate introduces the new OFF-X™ platform for preclinical and clinical safety intelligence

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the launch of the new OFF-X™ platform. The enhanced solution offers a seamless user experience and unique translational insights. It delivers crucial...

Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe

Galderma announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for RelfydessTM (RelabotulinumtoxinA – previously referred to as QM1114). RelfydessTM is indicated for the temporary improvement...

Lipella Pharmaceuticals initiates Phase 2a trial for LP-310 in oral lichen planus, enrolling the first patients

Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the...

Transposon announces Phase 2 results for TPN-101 in treating C9orf72-related ALS and frontotemporal dementia

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced final results from its Phase...

Prolacta Bioscience Leads in Human Milk Science, Regularly Reviewing Health Claims with FDA

Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products, takes its obligation to the critically ill and premature infants it serves, and to the doctors providing them with care, extremely...

MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

MAIA Biotechnology, Inc.a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune...

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341

Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory diseases, announced that the first patient has been dosed in its...

Cytonics Begins First-In-Human Phase 1 Clinical Study for CYT-108 in Osteoarthritis Knee Patients

Cytonics Corporation, a private biotechnology company developing biologic therapies for musculoskeletal ailments, announced initiation of enrollment for its Phase 1 clinical study of CYT-108. A recombinant variant of the alpha-2-macroglobulin...

Leqembi Secures Approval for Alzheimer's Disease Treatment in Hong Kong

BioArctic AB's partner Eisai announced that the Department of Health in Hong Kong has approved Leqembi® (brand name in Hong Kong, generic name: lecanemab) for treatment of Alzheimer's disease (AD). Treatment with Leqembi should be initiated in...

PharmAbcine's Phase 1 Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Single-Dose (4mg) and Multiple-Dose (3mg)

PharmAbcine, Inc. a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance PMC-403, its candidate treatment for neovascular age-related macular degeneration...

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Inc. a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, announced positive topline...

Hyundai Bioscience Develops Multi-Treatment for Mosquito-Borne Viral Infections, Including Dengue Feve

Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a 'multi-treatment drug for mosquito-borne viral infections, including dengue...